Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

16.7%

3 terminated/withdrawn out of 18 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

72%

13 trials in Phase 3/4

Results Transparency

107%

16 of 15 completed trials have results

Key Signals

16 with results

Enrollment Performance

Analytics

Phase 3
12(66.7%)
Phase 2
5(27.8%)
Phase 4
1(5.6%)
18Total
Phase 3(12)
Phase 2(5)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT02042183Phase 3Completed

Lubiprostone in Children With Functional Constipation

Role: lead

NCT02766777Phase 3Completed

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

Role: lead

NCT03010631Phase 3Completed

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Role: lead

NCT01298219Phase 3Completed

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Role: lead

NCT00620061Phase 3Completed

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Role: lead

NCT02138136Phase 3Completed

Lubiprostone for Children With Constipation

Role: lead

NCT03097861Phase 3Completed

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Role: lead

NCT02544152Phase 2Terminated

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Role: lead

NCT00597818Phase 2Completed

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

Role: lead

NCT00452335Phase 4Completed

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

Role: lead

NCT00399542Phase 3Completed

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Role: lead

NCT00595946Phase 3Completed

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Role: lead

NCT01993875Phase 3Completed

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

Role: collaborator

NCT01379560Phase 2Completed

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Role: lead

NCT00597428Phase 3Completed

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Role: lead

NCT02542215Phase 2Terminated

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

Role: lead

NCT00737594Phase 2Terminated

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Role: lead

NCT00380250Phase 3Completed

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Role: lead

All 18 trials loaded